Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESET-R: Immunotherapy in Early dMMR Rectal Cancer
NCT05732389Phase 2Recruiting
- Sponsor
- University Hospital Odense
- Start
- Feb 2023
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in rectal cancer, sponsored by University Hospital Odense. Started Feb 2023; status: recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05732389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05732389.